| Popis: |
To investigate the predictive value of methyltransferase EZH2 expression level on the clinical efficacy and long-term prognosis of patients with primary gastrointestinal diffuse large B-cell lymphoma (PGI-DLBCL).161 patients with newly treated PGI-DLBCL in our hospital from August 2013 to July 2019 were selected. The expression level of EZH2 protein was detected by immunohistochemistry, and the short-term efficacy and long-term survival differences of patients with different levels of EZH2 were compared. The predictive values of EZH2 expression level on the short-term efficacy and long-term prognosis of PGI-DLBCL patients were analyzed by Log-rank test and COX risk proportional regression model. Chi-square test and Logistic regression analysis were used to analyze the influencing factors of EZH2 expression level.The complete response (CR) and overal response(OR) rates of those with high EZH2 expression were significantly lower than those with low EZH2 expression (P0.001). The median OS and PFS of EZH2 high-level and low-level expression group was 37, 31 months and 49, 42 months, respectively. The cumulative OS and PFS rates of the high-level expression group were significantly lower than those of the low-level expression group, and the differences were statistically significant (P0.05). The high expression levels of H3K27me3, EZH2, BCL-2, BCL-6, c-MYC were closely related to the shortening of OS and PFS, while the high expression level of Ki-67 was closely related to the shortening of OS (P0.05), of which the high expression levels of H3K27me3, EZH2, BCL-2, and BCL-6 were independent risk factors for shortening of OS and PFS. The expression level of EZH2 was positively correlated with the expression level of H3K27me3, BCL-6, c-MYC and Ki-67 (r=0.741, r=0.837, r=0.809, r=0.772), and the high expression levels of H3K27me3, BCL-6 and Ki-67 were independent factors influencing the high expression of EZH2.In patients with PGI-DLBCL, the high expression of EZH2 significantly reduces the short-term CR and OR rates, which is an independent risk factor for the shortening of long-term OS and PFS rates, and it is independently related to the high expression of H3K27me3 and BCL6.甲基转移酶EZH2表达水平对原发性胃肠道弥漫大B细胞淋巴瘤患者临床疗效及远期预后的预测价值分析.探讨甲基转移酶EZH2表达水平对原发性胃肠道弥漫大B细胞淋巴瘤（PGI-DLBCL）患者的临床疗效及远期预后的预测价值.选择2013年8月-2019年7月本院161例初治的PGI-DLBCL患者，检测其EZH2蛋白表达水平，比较不同水平EZH2患者的近期疗效及远期生存差异；Log-rank检验及COX风险比例回归模型统计分析EZH2表达水平对PGI-DLBCL预后的预测价值；卡方检验及Logistic回归法分析EZH2表达水平的影响因素.EZH2高表达患者完全缓解率、总缓解率均明显低于低表达患者(P0.001)。EZH2高、低水平表达组中位总生存期（OS）及无进展生存期（PFS）分别为37、31个月和49、42个月，高水平表达组累积OS和PFS率均明显低于低水平表达组，差异均有统计学意义（P0.05）。H3K27me3、EZH2、BCL-2、BCL-6、c-MYC高表达与患者OS和PFS缩短密切相关，Ki-67高表达与患者OS缩短密切相关(P0.05)，其中H3K27me3、EZH2、BCL-2、BCL-6高表达为患者OS和PFS缩短的独立危险因素。EZH2表达水平与H3K27me3、BCL-6、c-MYC、Ki-67表达水平均呈正相关(r=0.741，r=0.837，r=0.809，r=0.772)，其中H3K27me3、BCL-6、Ki-67高表达为EZH2高表达的独立影响因素.在PGI-DLBCL患者中，EZH2高表达明显降低近期完全缓解率、总缓解率，是远期OS、PFS率缩短的独立危险因素，与H3K27me3、BCL-6高表达呈独立相关. |
